ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?

Bruna Pellini; Aadel A. Chaudhuri

doi:10.1158/1078-0432.CCR-23-0420

ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?

Bruna Pellini, Aadel A. Chaudhuri

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Small cell lung cancer (SCLC) is the deadliest form of lung cancer and has few precision medicine approaches available. A recent study analyzed circulating tumor DNA (ctDNA) in 33 patients with extensive-stage SCLC and showed that ctDNA levels and response patterns correlate strongly with clinical response and survival outcomes.

Original language	English
Pages (from-to)	2176-2178
Number of pages	3
Journal	Clinical Cancer Research
Volume	29
Issue number	12
DOIs	https://doi.org/10.1158/1078-0432.CCR-23-0420
State	Published - Jul 1 2023

Access to Document

10.1158/1078-0432.CCR-23-0420

Cite this

@article{ff2c4c76e5114a6eb74f000c62de2253,

title = "ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?",

abstract = "Small cell lung cancer (SCLC) is the deadliest form of lung cancer and has few precision medicine approaches available. A recent study analyzed circulating tumor DNA (ctDNA) in 33 patients with extensive-stage SCLC and showed that ctDNA levels and response patterns correlate strongly with clinical response and survival outcomes.",

author = "Bruna Pellini and Chaudhuri, {Aadel A.}",

note = "Publisher Copyright: {\textcopyright} 2023 American Association for Cancer Research. ",

year = "2023",

month = jul,

day = "1",

doi = "10.1158/1078-0432.CCR-23-0420",

language = "English",

volume = "29",

pages = "2176--2178",

journal = "Clinical Cancer Research",

issn = "1078-0432",

number = "12",

}

TY - JOUR

T1 - ctDNA Monitoring for Small Cell Lung Cancer

T2 - Ready for Prime Time?

AU - Pellini, Bruna

AU - Chaudhuri, Aadel A.

PY - 2023/7/1

Y1 - 2023/7/1

N2 - Small cell lung cancer (SCLC) is the deadliest form of lung cancer and has few precision medicine approaches available. A recent study analyzed circulating tumor DNA (ctDNA) in 33 patients with extensive-stage SCLC and showed that ctDNA levels and response patterns correlate strongly with clinical response and survival outcomes.

AB - Small cell lung cancer (SCLC) is the deadliest form of lung cancer and has few precision medicine approaches available. A recent study analyzed circulating tumor DNA (ctDNA) in 33 patients with extensive-stage SCLC and showed that ctDNA levels and response patterns correlate strongly with clinical response and survival outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85163265369&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-23-0420

DO - 10.1158/1078-0432.CCR-23-0420

M3 - Article

C2 - 37097069

AN - SCOPUS:85163265369

SN - 1078-0432

VL - 29

SP - 2176

EP - 2178

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 12

ER -

ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?

Abstract

Access to Document

Other files and links

Fingerprint

Cite this